VNS Therapy for TRD
Treatment-Resistant Depression
Key Facts
Indication
Treatment-Resistant Depression
Phase
PMA Supplement
Status
Active - Commercial Expansion
Company
About LivaNova
LivaNova PLC is a publicly traded medical device company formed from the strategic merger of Sorin Group and Cyberonics, unifying cardiovascular and neuromodulation expertise. Its mission is to change the trajectory of lives through two core platforms: VNS Therapy™ for neurological disorders and the Essenz™ Perfusion System for cardiopulmonary surgery. The company has established strong commercial footprints in both therapeutic areas and is advancing its pipeline to expand indications and integrate digital health capabilities. LivaNova's strategy hinges on leveraging deep clinical evidence, driving operational excellence, and pursuing disciplined innovation to address significant unmet medical needs.
View full company profileTherapeutic Areas
Other Treatment-Resistant Depression Drugs
| Drug | Company | Phase |
|---|---|---|
| DB104 (Liafensine) | Denovo Biopharma | Phase 2b |
| Precision Radiomodulation Research | ZAP Surgical | Feasibility Study |
| NOE-101 (basimglurant) | Noema Pharma | Phase 2b |
| PCN-101 (R-ketamine) | Perception Neuroscience | Phase 2a |
| mGlu2 NAM Program for TRD | Camino Pharma | Pre-clinical |
| TAK-653 | Thermo Fisher Scientific | Phase 2 |
| SPN-820/821 | Supernus Pharmaceuticals | Phase 3 |
| BPL-003 | atai Life Sciences | Phase 2 |
| VLS-01 | atai Life Sciences | Phase 2 |